Migraine Disability Assessment Score (MIDAS)
Migraine Disability Assessment Score · Also known as: MIDAS Scale, Migraine Disability Assessment
The MIDAS is a brief, five-item self-report questionnaire that quantifies migraine-related disability by measuring days lost from work, school, household activities, and family/social activities over a 3-month period. Introduced by Stewart and colleagues in 1999, it is the most widely used measure of migraine burden in clinical practice and research. MIDAS directly translates migraine frequency and severity into functional impact (lost productivity, lost days), enabling healthcare providers and patients to understand the true disability burden of migraines.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
MIDAS is ideal for rapid assessment of migraine-related disability in primary care or specialty clinics to inform preventive treatment decisions. Use in clinical trials measuring migraine prevention effectiveness (is preventive therapy reducing disability days?). Use in observational studies characterizing migraine burden across populations. Use in health economic analyses quantifying workplace productivity loss and treatment cost-effectiveness. Use in patient counseling to quantify disease burden and justify preventive treatment initiation. Less suitable when detailed quality-of-life assessment beyond disability days is needed (use Migraine-Specific QoL questionnaire); MIDAS focuses narrowly on lost days, not pain or emotional impact.
Strengths & limitations
- Extreme brevity (5 items, <2 minutes) and simplicity make it practical for routine clinic use and enables administration to large populations in research
- Directly measures functional impact (lost productivity days) that matters to patients and employers, enabling translation to economic burden
- Strong validity and reliability demonstrated across diverse migraine populations and studies; widely accepted in regulatory and clinical contexts
- Actionable: grades clearly inform treatment decisions; Grade III-IV patients are candidates for preventive therapy initiation or escalation
- Universally applicable across migraine types (episodic, chronic, with/without aura); no disease subtype limitations
- Relies on patient recall of days lost over 3 months; recall bias can inflate or deflate disability assessment, especially in frequent migraineurs
- Measures only lost days, not pain severity, quality of life, or emotional impact; does not capture full migraine burden in those dimensions
- Weighting assumption implicit in MIDAS is that all lost days are equally important; in reality, a patient with 4 severe migraines per month losing all 4 days may be more disabled than one with 20 mild migraines losing 20 days
- May not discriminate well in very low-burden (Grade I) or very high-burden (Grade IV with >50 lost days) populations due to ceiling/floor effects in these grades
Frequently asked
What is the relationship between MIDAS and migraine pain intensity?
MIDAS (disability) and pain intensity are related but distinct. A patient with high pain intensity may have low MIDAS if pain is brief or migraines infrequent. A patient with moderate pain but frequent migraines may have high MIDAS. Both matter: pain management is important, but MIDAS better predicts functional impact and disability burden. Ideally, assess both pain (e.g., numeric scale 0-10) and MIDAS (disability) to fully characterize migraine burden.
If a patient scores MIDAS Grade IV, does that automatically mean they need preventive medication?
MIDAS Grade IV (≥21 lost days per 3 months) is a clear indicator for considering preventive therapy and warrants discussion with the patient. However, treatment decisions involve multiple factors: patient preference, contraindications to specific preventives, presence of other treatable contributors (medication overuse, sleep, stress). A Grade IV patient who accepts the burden and declines preventives should be respected; clinical judgment and shared decision-making are paramount.
How accurate is MIDAS recall? Should I use a migraine diary instead?
MIDAS retrospective recall (3-month period) has reasonable accuracy for average migraineurs (4-8 per month), but accuracy declines with very frequent migraines (>15 per month) due to recall bias. For research requiring high precision, prospective migraine diary (patient records each migraine real-time) is more accurate. For clinic use, MIDAS is practical and sufficiently accurate for disability grading and treatment decisions. Consider diary if MIDAS seems inaccurate or patient has very frequent migraines.
Is MIDAS useful in chronic migraine (≥15 headache days per month)?
MIDAS can be used in chronic migraine but has limitations. Chronic migraine patients frequently score Grade IV (>21 days), with less discrimination across severity levels. For chronic migraine, MIDAS is useful as a baseline and to track improvement with prevention, but supplementary measures (migraine-specific QoL, pain intensity, headache frequency) provide additional information about burden and treatment response.
Sources
- Stewart, W. F., Lipton, R. B., Dowson, A. J., & Sawyer, J. (1999). Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire. Neurology, 53(Suppl 3), S23-S28. DOI: 10.1037/t12116-000 ↗
How to cite this page
ScholarGate. (2026, June 3). Migraine Disability Assessment Score. ScholarGate. https://scholargate.app/en/neurology/migraine-disability-assessment
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
Compare side by side →